Coronavirus vaccine update: We may need a booster shot for COVID-19 vaccine; here’s what it means
NEW DELHI: The All India Institute of Medical Sciences (AIIMS) in Delhi is scheduled to start phase I/II of human clinical trials of the indigenously developed Covid-19 vaccine candidate 'Covaxin' on Monday. AIIMS Delhi is among the 12 sites where human trials for Covaxin will be conducted. Here is all you need to know about AIIMS trials:* The human trial at AIIMS (Delhi) have started after Drugs Controller General of India (DCGI), India's top drug regulator, had recently given a green signal for Covaxin human clinical trials. * Covaxin has been developed by the Hyderabad-based Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV). * AIIMS (Delhi) had registered a
NEW YORK: Global healthcare company Johnson & Johnson is planning to start a Phase-3 clinical trial of its Covid-19 vaccine ahead of its original schedule, potentially in late September, said a top executive of the company. Johnson & Johnson is in talks with the US National Institute of Health to start the late stage trial of the vaccine ahead of schedule, Paul Stoffels, the Chief Scientific Officer of the company said during an earnings call with investors on Thursday. J & J announced its lead Covid-19 vaccine candidate on March 30. Preclinical data on the vaccine were published in the Journal of Science in May. The company moved ahead with a study of a final Ad26.COV2-S, recombinant, vaccine candidate in
As per a report published in Reuters, the Lancet medical journal said on Wednesday it will publish keenly-awaited phase 1 clinical trial data on a potential COVID-19 vaccine being developed by Astrazeneca and Oxford University on Monday."We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release," a spokeswoman for the journal said.
Billionaire and philanthropist, Bill Gates, known for his work towards promoting public healthcare voiced his opinion regarding the same. Speaking to a media house, the 64-year-old said that all vaccine companies should ensure that vaccines in work should be made available to all sections of the public, and not make it into a transactional deal:“If we just let drugs and vaccines go to the highest bidder, instead of to the people and the places where they are most needed, we’ll have a longer, more unjust deadlier pandemic,”The comments came in the backdrop of rich countries, such as the US and Europe investing millions into the global vaccine race and claims of a vaccine being made available for a certain country
BEIJING: A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday. The early-stage trial, published in the Lancet, was conducted by researchers at several laboratories and included 108 participants ages 18 to 60. Those who received a single dose of the vaccine produced certain immune cells, called T cells, within two weeks. Antibodies needed for immunity peaked at 28 days after the inoculation. "This is promising data, but it’s early data," said Dr. Daniel Barouch, director of vaccine research at Beth Israel Deaconess Medical Center in Boston, who was not involved in the work. "Overall, I would say this is good news." Covid-19: Live updates The trial is the first step in